<SEC-DOCUMENT>0001213900-23-074964-index.html : 20230907
<SEC-HEADER>0001213900-23-074964.hdr.sgml : 20230907
<ACCEPTANCE-DATETIME>20230907160131
ACCESSION NUMBER:		0001213900-23-074964
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230907
FILED AS OF DATE:		20230907
DATE AS OF CHANGE:		20230907

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		231242216

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea184847-6k_scisparc.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
Document 1 - file: ea184847-6k_scisparc.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea184847ex99-1_scisparc.htm
<DESCRIPTION>SCISPARC ANNOUNCES INITIATION OF RANDOMIZED PHASE IIB CLINICAL TRIAL OF ITS PROPRIETARY SCI-110 FOR TOURETTE SYNDROME
<TEXT>
Document 2 - file: ea184847ex99-1_scisparc.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ea184847ex99-2_scisparc.htm
<DESCRIPTION>SCISPARC GRANTED 180-DAY EXTENSION BY NASDAQ TO REGAIN COMPLIANCE WITH MINIMUM BID REQUIREMENT
<TEXT>
Document 3 - file: ea184847ex99-2_scisparc.htm

</DOCUMENT>
</SEC-DOCUMENT>